

## **Disclosures**

#### Personal Commercial (7)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Alnylam	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Eidos	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Eidos	Research/Research Grants ‡ Investigator Initiated Study - TTR-specific biomarkers in the Dallas Heart Study	None (\$0)	Heart Failure and Cardiomyopathies
Eidos	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Pfizer	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Pfizer Inc	Research/Research Grants ‡ NCT05489523	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies

## Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

# Personal Organizational or Other Non-Commercial (0)

No disclosures on record

## Clinical Trial Enroller (3)

Trial Name	Trial Sponsor	Trial Funding Source
CARDIOTTRansform	AstraZeneca Pharmaceuticals	
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants	Eidos/BridgeBio	
MUSIC-HFrEF1	Sardocor	

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

## Certified Education Attestation | Signed on 8/17/2023

 $\textit{URL for full agreement: http://disclosures.acc.org/Public/Definition/Certified Education Attest at ion Agreement agreement$ 

#### Confidentiality, Disclosure and Assignment Agreement | Signed on 8/17/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureand Assignment Agreement

Embargo | Signed on 8/17/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

#### On-Going Obligation Agreement | Signed on 8/17/2023

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.